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more economically effective alternative drug but it can be used only as second or third 
line of treatment with biological drugs according to Russian standards of rheumatoid 
arthritis’ management.
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OBJECTIVES: This study seeks to compare the cost-effectiveness of bisphosphonates 
for the treatment and prevention of post-menopausal osteoporosis (PMO). 
METHODS: A literature review was conducted to obtain all relevant articles pub-
lished through the end of 2009 that evaluate the cost-effectiveness of bisphosphonates 
for the treatment and prevention of PMO. PubMed and the Cochrane Database 
were used to search for the terms “bisphosphonates” and “cost-effectiveness.” 
Articles were limited to those evaluating at least one of the four products with an 
indication approved by the United States Food and Drug Administration for PMO: 
alendronate, ibandronate, risedronate, or zoledronic acid. Articles focusing on screen-
ing efforts, or evaluating the treatment of men, glucocorticoid-induced osteoporosis, 
or cancer-related bone complications were excluded. A manual review of the included 
articles’ references was also performed. RESULTS: The literature search resulted in 
189 articles of which 18 met the criteria for inclusion in this evaluation. Of these 
18 studies, many examined the use of more than one bisphosphonate, therefore, the 
total number of comparisons identiﬁed for alendronate, ibandronate, risedronate, 
and zoledronic acid were 13, 3, 8, and 1, respectively. The incremental cost- 
effectiveness ratios obtained from this analysis varied greatly for all included agents: 
alendronate ranged from −$25,296.12 (cost-savings) to $934,883.71; ibandronate 
from $10,354.68 to $15,023.90; risedronate from $1,468.75 to $241,410.15; and 
zoledronic acid from $1,791.42 to $2,205.39. These results varied based on the 
included women’s age and underlying risk factors, the speciﬁc costs accounted for 
in each analysis, and the total duration of treatment. CONCLUSIONS: Bisphospho-
nates represent cost-effective treatment options for the prevention and treatment of 
PMO. Given the evidence available, it is difﬁcult to determine whether one agent 
is conclusively more cost-effective than another for this indication. Further studies 
directly comparing bisphosphonates should be conducted to evaluate their compara-
tive cost-effectiveness.
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OBJECTIVES: To conduct a systematic review of economic analyses of biologic 
therapies in patients with ankylosing spondylitis (AS) METHODS: A systematic 
literature search was conducted by one researcher from January, 2000 to January, 
2009 using Pubmed, Evidence-Based Medical Reviews, and Medline databases to 
identify all economic studies of biologic therapies in AS. Search key terms included 
ankylosing spondylitis, biologics, Adalimumab, Inﬂiximab, Etanercept, cost, phar-
macoeconomics, and combination of search terms. The Quality of Health Economic 
Studies (QHES) instrument was used to assess the quality of economic studies 
included in the ﬁnal review. RESULTS: The initial search yielded nine studies out 
of which three review studies were excluded. The remaining six studies compared 
the biologics Etanercept, Inﬂiximab, and Adalimumab against comparators such as 
NSAIDs and placebo. One study employed a cost-effective analysis (cost/BASDAI 
score), while the remaining studies employed cost-utility analysis (cost/QALYs). Inf-
liximab and Adalimumab were found to be cost-effective compared to NSAIDs and 
placebo with a CE ratio of $10,000/QALY (US) and £5,093/QALY (UK). A com-
binational therapy of Etanercept and NSAIDs was found to be cost-effective (£ 
25,000, UK) versus NSAIDs. A combination of Inﬂiximab and Etanercept versus 
NSAIDs alone was not cost-effective (Etanercept 342,494/QALY, Inﬂiximab 367,207/
QALY). CONCLUSIONS: In most studies the CE ratio of Adalimumab and Inﬂix-
imab was below the accepted threshold of $50,000/QALY (US) and £25,000/ QALY 
(UK). However, a study conducted in the The Netherlands did not approve the 
combinational use of Inﬂiximab and Etanercept in the treatment of AS, since 
the total treatment cost was higher than the accepted threshold of 318,000/QALY. 
The results in different studies varied because of underlying study assumptions and 
different study methodologies. Clinical decision-makers must take into account 
country and model-speciﬁc parameters in order to make decisions on the use of 
biologics in AS.
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OBJECTIVES: The clinical burden associated with osteoporotic vertebral body com-
pression fracture (VCF) has been well documented in the literature. Less information 
is available on the economics of interventions for treatment of VCF—including ver-
tebroplasty and kyphoplasty—which are reported to be equally efﬁcacious options for 
patients suffering from this debilitating condition. This study seeks to quantify hospital 
costs associated with vertebroplasty and kyphoplasty. METHODS: Analysis of hos-
pital discharge and billing records extracted from the Premier Perspective™ database, 
2007–2008. The Premier database contains clinical and ﬁnancial information from 
over 600 hospitals. Independent-sample t tests were used to test for between-group 
differences in total and department-speciﬁc direct medical costs incurred during the 
index inpatient or outpatient procedure. RESULTS: A total of 3617 patients received 
vertebroplasty (64% inpatient and 36% outpatient) and 8,118 received kyphoplasty 
(54% inpatient and 46% outpatient) for treatment of VCF. Patients in the vertebro-
plasty group had a mean age of 78, and patients in the kyphoplasty group had a mean 
age of 76. More patients in the vertebroplasty group (14.5%) had an APR-severity 
rating of “major” or “extreme” than patients in the kyphoplasty group (9.5%). Mean 
total inpatient costs were $9,837 for vertebroplasty compared to $13,187 for kypho-
plasty (p < 0.0001). Mean total outpatient costs were $3,319 for vertebroplasty 
compared to $8,100 for kyphoplasty (p < 0.0001). Adjustments to control for differ-
ences in age, sex, admission status, and disease severity accentuate these differences. 
CONCLUSIONS: Compared to kyphoplasty, vertebroplasty is a cost-minimizing 
option for treatment of VCF, reducing hospital costs by nearly $5000 for outpatient 
procedures and by more than $3000 for inpatient procedures. These differences 
occurred despite older age and greater disease severity for patients in the vertebro-
plasty group. Further research is necessary to evaluate the incremental cost effective-
ness of treatment options for VCF.
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OBJECTIVES: The objective was to compare Etanercept and Adalimumab in terms 
of adequacy of recommended indications and of the health care costs. METHODS: 
This survey of cost minimization was performed by an ofﬁce based pharmacist panel 
answering to a questionnaire at the moment of the delivery of one among two ambula-
tory biologics, Etanercept and Adalimumab. RESULTS: The results show that these 
biologics are mainly prescribed in rheumatology, 94% and 79% for Etanercept and 
Adalimumab respectively. The prescriptions are consistent with recommended indica-
tions for both products. In rheumatology, the retailing of consumption by pathology 
is closed for the two treatments. The follow of treatment scheme and of the associated 
costs have been realized only for the adult rheumatologic indications. At 93.8%, 
“Etanercept 50 mg” is prescribed at the recommended dosage. In 2.2 % of cases, the 
dosage increased at two injections per week and decreased at one injection all 2 weeks 
in 2.5 % of cases. For Adamimumab, 82.6 % treatments followed the recommended 
dosage, 3.6 % at an inferior dosage and 13.8 % at a superior dosage with one or two 
injections per week. The differential between the recommended treatment scheme and 
the common practice have a direct impact on the annual treatment cost. The health 
care costs with Etanercept appeared less expensive. The mean annual cost per patient 
is of 312,566 with Etanercept and of 316,252 with Adalimumab. CONCLUSIONS: 
This survey demonstrates that the health care cost is 29% superior with Adalimumab. 
The health care with Etanercept seems to have a better stability of the recommended 
treatment scheme.
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OBJECTIVES: To determine which tumor necrosis factor-alpha (TNF-alpha) inhibitor 
is the most cost-effective agent for the treatment of rheumatoid arthritis. METHODS: 
A Markov model was designed to analyze the cost-utility of certolizumab, etanercept, 
adalimumab and golimumab versus inﬂiximab (with methotrexate) for the treatment 
of moderately to severely active rheumatoid arthritis from a U.S. health care payer 
perspective. A cohort of 10,000 patients was simulated using half-cycle correction 
with a cycle length of three months for a total of ﬁve years. The probability of achiev-
ing ACR70, serious infections, and hospitalization were based on data from published 
literature and assumed to follow a beta distribution. Utility scores were based on a 
published report using a visual analog scale. Costs were adjusted for 2009 U.S. dollars 
using the medical consumer price index and a discount rate of 3% per annum. Cost 
and utility scores were assumed to follow a gamma distribution. Probabilistic sensitiv-
ity analysis (PSA) was performed to test the robustness of the base-case model. 
RESULTS: Certolizumab, etanercept, adalimumab and golimumab were dominant 
compared to inﬂiximab with incremental cost-effectiveness ratios (ICERs) of 
−$101,377.60, −$137,606.34, −$102,689.18, and −$63,415.60/additional QALY 
gained, respectively. The cost-effectiveness ratios of certolizumab, etanercept, adalim-
umab, golimumab, and inﬂiximab were $6325.62, $6467.41, $6595.43, $6903.74, 
and $7508.16, respectively. Certolizumab resulted in the lowest cost and highest gain 
in QALYs compared to all comparators. In the PSA, there was a higher proportion 
of ICERs that were cost-effective with certolizumab (91.06%), etanercept (85.89%), 
adalimumab (84.67%), and golimumab (79.23%) when compared to inﬂiximab at a 
willingness-to-pay (WTP) of $60,000. The acceptability curve showed that certoli-
zumab had a higher probability of being cost-effective compared to all other compara-
tors at a WTP of $60,000/additional QALY gained. CONCLUSIONS: At a $60,000 
